Treatment of Menopause
Menopause marks the end of menstrual cycles after 12 consecutive months without a period, typically in women's late 40s to early 50s. Significant hormonal changes cause wide-ranging symptoms.
Menopause marks the end of menstrual cycles after 12 consecutive months without a period, typically in women's late 40s to early 50s. Significant hormonal changes cause wide-ranging symptoms.
First-Line Treatment Principles
- ✓Identify underlying cause: hormonal, structural, tubal, male factor, or unexplained
- ✓Lifestyle optimisation before fertility treatment: weight, smoking, folic acid
- ✓Ovulation induction with clomifene or gonadotrophins for anovulatory infertility
- ✓IVF/ICSI when other approaches have failed or irreversible causes (tubal occlusion, severe male factor)
- ✓HRT for menopausal symptoms: lowest effective dose for shortest duration
Medications Used in Menopause
Ethinylestradiol is a hormonal agent used for contraception, hormone replacement therapy, or the management of menstrual and gynecological disorders.
Levonorgestrel is a hormonal agent used for contraception, hormone replacement therapy, or the management of menstrual and gynecological disorders.
Norethisterone is a hormonal agent used for contraception, hormone replacement therapy, or the management of menstrual and gynecological disorders.
Desogestrel is a hormonal agent used for contraception, hormone replacement therapy, or the management of menstrual and gynecological disorders.
Drospirenone is a hormonal agent used for contraception, hormone replacement therapy, or the management of menstrual and gynecological disorders.
Medroxyprogesterone is a hormonal agent used for contraception, hormone replacement therapy, or the management of menstrual and gynecological disorders.
Progesterone is a hormonal agent used for contraception, hormone replacement therapy, or the management of menstrual and gynecological disorders.
Tibolone is a hormonal agent used for contraception, hormone replacement therapy, or the management of menstrual and gynecological disorders.
Non-Pharmacological Management
- •Weight management: BMI 18.5–25 kg/m² optimises conception rates and reduces obstetric complications
- •Folic acid 400mcg/day: before conception and for 12 weeks in pregnancy (5mg in high-risk)
- •Smoking cessation and alcohol avoidance: improve fertility and reduce miscarriage
- •Regular exercise: moderate-intensity; avoid extreme exercise that suppresses ovulation
- •Stress reduction and psychological support during fertility treatment
- •Pelvic floor physiotherapy: for pelvic pain, prolapse, and urinary incontinence
Treatment Goals
Monitoring Parameters
- ◆Day 21 progesterone: confirm ovulation
- ◆AMH (anti-Müllerian hormone) and antral follicle count: ovarian reserve assessment
- ◆Semen analysis: concentration, motility, morphology — both partners assessed
- ◆Transvaginal ultrasound: follicle monitoring during stimulation cycles
- ◆Endometrial thickness: before embryo transfer (>7mm adequate)
- ◆HCG levels: early pregnancy monitoring; doubling every 48h confirms viable implantation
Escalation Criteria
- →Ovarian hyperstimulation syndrome (OHSS): freeze-all embryos if severe; hospitalisation if critical
- →Ectopic pregnancy: urgent surgical or medical (methotrexate) management
- →Recurrent pregnancy loss (≥3): full investigation panel; specialist reproductive medicine referral
- →Endometriosis not responding to medical therapy → laparoscopic surgery consideration
Special Populations
Clinical Insights
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →